Friday, October 4, 2024
8:46 AM EST – Oncolytics Biotech Inc : Today issued a corporate update to provide investors with a deeper understanding of recent data and what is expected for 2025. Recent clinical efficacy results from the BRACELET-1 trial in HR+/HER2- breast cancer pave the way for a clinical study designed to support an accelerated approval. Key milestones in gastrointestinal cancer clinical trials are expected in 2025, with potential for new registration-enabling studies. Oncolytics Biotech Inc (T.ONC) shares were up $0.07 at 1.27.
Stocks in Play: Oncolytics Biotech Inc , Fri, 04 Oct 2024 08:57:06 EST